Compare · BSX vs SKYA
BSX vs SKYA
Side-by-side comparison of Boston Scientific Corporation (BSX) and SkyAI Inc. (SKYA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BSX and SKYA operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BSX is the larger of the two at $64.27B, about 544.7x SKYA ($118.0M).
- BSX has been more active in the news (12 items in the past 4 weeks vs 7 for SKYA).
- BSX has more recent analyst coverage (25 ratings vs 0 for SKYA).
- Company
- Boston Scientific Corporation
- SkyAI Inc.
- Price
- -
- -
- Market cap
- $64.27B
- $118.0M
- 1M return
- +0.43%
- -
- 1Y return
- -56.81%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 12
- 7
- Recent ratings
- 25
- 0
Boston Scientific Corporation
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
SkyAI Inc.
SkyAI, Inc. (Nasdaq: SKYA) is an artificial intelligence company building an agentic finance platform for the Global South. The Company uses AI to deliver financial access, education and actionable intelligence globally.
Latest BSX
- Chairman, President & CEO Mahoney Michael F received a gift of 252,241 shares (SEC Form 4)
- SVP, Chief HR Officer O'Sullivan Miriam converted options into 3,871 shares and covered exercise/tax liability with 1,872 shares, increasing direct ownership by 11% to 19,565 units (SEC Form 4)
- Blackstone Life Sciences Announces $455 Million Collaboration to Co-Fund Development of Boston Scientific VITALYST™ Heart Pump for Patients with Cardiogenic Shock
- SEC Form 10-Q filed by Boston Scientific Corporation
- SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
- Boston Scientific downgraded by TD Cowen with a new price target
- Penumbra, Inc. Reports Third Quarter 2026 Financial Results
- Boston Scientific downgraded by Oppenheimer
- Boston Scientific downgraded by Analyst with a new price target
- SEC Form 8-K filed by Boston Scientific Corporation
Latest SKYA
- SkyAI Announces Preliminary Results of Cash Tender Offer
- SkyAI Files Amended Tender Offer Documents and Reminds Security Holders To Tender Before the November 12, 2026 Expiration
- Bastion Trading Limited Reaches Agreement with SkyAI for Amendments to Tender Offer and Announces That It Will Tender All of Its SkyAI Securities
- SkyAI Enters into Tender Support and Settlement Agreement with Bastion Trading Limited; Extends Cash Tender Offer to All Pre-Funded Warrants and Includes All Stapled Warrants
- Third Eye Supports Bastion Trading's October 21 Call for Improved SkyAI Tender Terms
- Bastion Trading Calls on SkyAI Chairman and Directors to Demonstrate Accountability and to Provide a Better Tender Offer for All Stockholders and Pre-Funded Warrant Holders
- SkyAI Commences Cash Tender Offer to Purchase Up to 67.1 Million Shares and Warrants
- SkyAI to Commence $3.00 Per Share/Warrant Tender Offer and File Offer Materials with the SEC After Market Close on October 15, 2026
- Bastion Trading Challenges SkyAI’s Proposed Tender Offer, Demands Immediate and Full Disclosure of SOL Sales and Board Reconstitution
- SkyAI Announces Intention to Commence Cash Tender Offer to Purchase Common Stock and Pre-funded Warrants at $3.00 Per Share/Pre-funded Warrant